The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Lucentis (Ranibizumab) and Biosimilar Market Research Report 2025

Global Lucentis (Ranibizumab) and Biosimilar Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1739062

No of Pages : 74

Ask Your Query

Synopsis
Ranibizumab is a medication used to manage and treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy.

Global Lucentis (Ranibizumab) and Biosimilar market is projected to reach US$ 843.4 million in 2029, increasing from US$ 1124 million in 2022, with the CAGR of -2.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Lucentis (Ranibizumab) and Biosimilar market research.

Key manufacturers engaged in the Lucentis (Ranibizumab) and Biosimilar industry include Roche, Coherus and Biogen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Lucentis (Ranibizumab) and Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Lucentis (Ranibizumab) and Biosimilar market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Lucentis (Ranibizumab) and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Roche
  • Coherus
  • Biogen

Segment by Type

  • Brand
  • Biosimilar

Segment by Application

  • Hospital
  • Pharmacy
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Lucentis (Ranibizumab) and Biosimilar report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Lucentis (Ranibizumab) and Biosimilar Market Overview
1.1 Product Overview and Scope of Lucentis (Ranibizumab) and Biosimilar
1.2 Lucentis (Ranibizumab) and Biosimilar Segment by Type
1.2.1 Global Lucentis (Ranibizumab) and Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Lucentis (Ranibizumab) and Biosimilar Segment by Application
1.3.1 Global Lucentis (Ranibizumab) and Biosimilar Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Lucentis (Ranibizumab) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Lucentis (Ranibizumab) and Biosimilar Revenue 2018-2029
1.4.2 Global Lucentis (Ranibizumab) and Biosimilar Sales 2018-2029
1.4.3 Global Lucentis (Ranibizumab) and Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Lucentis (Ranibizumab) and Biosimilar Market Competition by Manufacturers
2.1 Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Lucentis (Ranibizumab) and Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Lucentis (Ranibizumab) and Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Lucentis (Ranibizumab) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Lucentis (Ranibizumab) and Biosimilar, Product Type & Application
2.7 Lucentis (Ranibizumab) and Biosimilar Market Competitive Situation and Trends
2.7.1 Lucentis (Ranibizumab) and Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Lucentis (Ranibizumab) and Biosimilar Players Market Share by Revenue
2.7.3 Global Lucentis (Ranibizumab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Lucentis (Ranibizumab) and Biosimilar Retrospective Market Scenario by Region
3.1 Global Lucentis (Ranibizumab) and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Lucentis (Ranibizumab) and Biosimilar Global Lucentis (Ranibizumab) and Biosimilar Sales by Region: 2018-2029
3.2.1 Global Lucentis (Ranibizumab) and Biosimilar Sales by Region: 2018-2023
3.2.2 Global Lucentis (Ranibizumab) and Biosimilar Sales by Region: 2024-2029
3.3 Global Lucentis (Ranibizumab) and Biosimilar Global Lucentis (Ranibizumab) and Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Region: 2024-2029
3.4 North America Lucentis (Ranibizumab) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Lucentis (Ranibizumab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2029)
3.4.3 North America Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Lucentis (Ranibizumab) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Lucentis (Ranibizumab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Lucentis (Ranibizumab) and Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Lucentis (Ranibizumab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Lucentis (Ranibizumab) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Lucentis (Ranibizumab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Lucentis (Ranibizumab) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Lucentis (Ranibizumab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Lucentis (Ranibizumab) and Biosimilar Sales by Type (2018-2029)
4.1.1 Global Lucentis (Ranibizumab) and Biosimilar Sales by Type (2018-2023)
4.1.2 Global Lucentis (Ranibizumab) and Biosimilar Sales by Type (2024-2029)
4.1.3 Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Lucentis (Ranibizumab) and Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Lucentis (Ranibizumab) and Biosimilar Sales by Application (2018-2029)
5.1.1 Global Lucentis (Ranibizumab) and Biosimilar Sales by Application (2018-2023)
5.1.2 Global Lucentis (Ranibizumab) and Biosimilar Sales by Application (2024-2029)
5.1.3 Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Lucentis (Ranibizumab) and Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Lucentis (Ranibizumab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Roche Lucentis (Ranibizumab) and Biosimilar Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Coherus
6.2.1 Coherus Corporation Information
6.2.2 Coherus Description and Business Overview
6.2.3 Coherus Lucentis (Ranibizumab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Coherus Lucentis (Ranibizumab) and Biosimilar Product Portfolio
6.2.5 Coherus Recent Developments/Updates
6.3 Biogen
6.3.1 Biogen Corporation Information
6.3.2 Biogen Description and Business Overview
6.3.3 Biogen Lucentis (Ranibizumab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Biogen Lucentis (Ranibizumab) and Biosimilar Product Portfolio
6.3.5 Biogen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Lucentis (Ranibizumab) and Biosimilar Industry Chain Analysis
7.2 Lucentis (Ranibizumab) and Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Lucentis (Ranibizumab) and Biosimilar Production Mode & Process
7.4 Lucentis (Ranibizumab) and Biosimilar Sales and Marketing
7.4.1 Lucentis (Ranibizumab) and Biosimilar Sales Channels
7.4.2 Lucentis (Ranibizumab) and Biosimilar Distributors
7.5 Lucentis (Ranibizumab) and Biosimilar Customers
8 Lucentis (Ranibizumab) and Biosimilar Market Dynamics
8.1 Lucentis (Ranibizumab) and Biosimilar Industry Trends
8.2 Lucentis (Ranibizumab) and Biosimilar Market Drivers
8.3 Lucentis (Ranibizumab) and Biosimilar Market Challenges
8.4 Lucentis (Ranibizumab) and Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock